CD274 and neoplasm: Several biomarkers have been identified which predict tumor responsiveness to immunotherapy including PD-L1 immunohistochemistry staining, tumor mutation burden (TMB), predicted neoantigen load, mismatch repair deficiency, and pre-existing immune cell infiltration [69].